Growth momentum Recent leadership changes and a successful Series D financing signal strengthened execution capability and strategic investment, presenting an opportunity to engage C-suite stakeholders about expansion plans, new product pilots, and broader market reach.

Vivally expansion Launch of the Vivally System and dedicated product leadership roles indicate a growing product portfolio and pipeline in non-invasive neuromodulation; approach product marketing, clinical education, and payer strategies to accelerate adoption and market access.

Neuromodulation focus Non-invasive closed-loop bladder neuromodulation aligns with broader demand for minimally invasive therapies; prospect for partnerships or pilot programs with urology clinics, healthcare systems, and digital health platforms to scale usage.

payer readiness Appointment of market access and payer relations leadership coupled with Series C funding suggests a push to secure favorable reimbursement; align with health plans, hospital networks, and value-based care programs for coverage and patient access.

Strategic partnerships International funding signals and a global growth mindset present opportunities to explore co-development, distribution, and telehealth integrations with medical device distributors, regional partners, and SAAS-enabled care platforms.